Renaissance Technologies - MOONLAKE IMMUNOTHERAPEUTICS ownership

MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 34 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of MOONLAKE IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2023$764
-3.4%
13,396
-13.6%
0.00%0.0%
Q2 2023$791
+62.8%
15,500
-31.7%
0.00%0.0%
Q1 2023$486
+298.4%
22,700
+95.5%
0.00%
Q4 2022$12211,6090.00%
Other shareholders
MOONLAKE IMMUNOTHERAPEUTICS shareholders Q4 2022
NameSharesValueWeighting ↓
BVF INC/IL 21,751,284$1,239,823,18833.43%
Cormorant Asset Management, LP 8,142,100$464,099,70027.07%
Ally Bridge Group (NY) LLC 183,105$10,436,98512.25%
Finepoint Capital LP 331,416$18,890,7129.41%
Ghost Tree Capital, LLC 330,000$18,810,0006.19%
5AM Venture Management, LLC 313,210$17,852,9705.14%
Ghost Tree Capital, LLC 250,000$14,250,0004.69%
MPM BioImpact LLC 294,190$16,768,8304.48%
Integral Health Asset Management, LLC 500,000$28,500,0003.95%
Altium Capital Management LP 88,000$5,016,0002.62%
View complete list of MOONLAKE IMMUNOTHERAPEUTICS shareholders